HIV Vaccine Trials Network, Member Protocol Committee 2007-Present;Protocol Co-Chair HVTN 906 Longitudinal study of women at high risk for HIV-1 infection to inform HIV vaccine trial participation 2009-Present;Protocol Chair HVTN 085 A phase 1b randomized double-blind clinical trial to examine whether polytopic administration of VRC rAd5 gag-pol/env A/B/C vaccine enhances HIV-specific cellular immune responses in humans 2010-Present
Protocol Co-chair, HVTN 090, A phase 1 clinical trial to evaluate the safety and immunogenicity of VSV-IN HIV gag vaccine given intramuscularly in healthy, HIV-1–uninfected adult participants, 2011 - present.
Protocol Chair, PDPHV 2011, A Phase I clinical trial to evaluate the safety and immunogenicity of Polyvalent env (A, B, C, D, E)/gag (C) DNA prime and gp 120 (A,B,C,D,E) Protein/ISCOMATRIX boost HIV-1 Vaccine-2011 (PDPHV-2011) in healthy, HIV-1 uninfected adult participants (in development); 2011 - present.
Member, HVTN Network Communication Working Group, 2011 - present
Member, Training and Education Committee, 2013 - present